CheckMate 9ER: Nivolumab–cabozantinib boosts advanced RCC outcomes

Andrea Apolo gives a top-line overview of the CheckMate 9ER study of nivolumab and cabozantinib, which she believes has added another option to the armamentarium for treatment-naïve, advanced renal cell carcinoma (4:00)